Breaking

Champions Cup has a jeopardy problem: can anyone stop the Top 14 giants? The play that changed my life: ‘I was the badass queen in Titus Andronicus – we did it like A Nightmare on Elm Street’ Enter the Zachbot: Trump’s new press secretary malfunctions on podium debut Republic of Ireland to 'lock in' for World Cup dream Royal Mail losing 400 postal workers a week, says union Saka responds to Arteta's challenge with 'huge impact' Robot seized by German police after allegedly groping teenage girl ‘Chip on his shoulder’: Brian Flores lawyers condemn racial stereotypes in NFL coaching report Texas DA says ICE intentionally hit immigrant with a car and may have withheld evidence Ohtani has 'great conversation' with Roberts, will be in Dodgers' Game 3 lineup

NEWSREEL

The day, in 30-second reels.

--:--:--

Tech / Reel

Tech · Video brief

Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Science Corporation has successfully implanted its vision-restoring chip in the first patient with Stargardt disease. The tiny PRIMA implant, placed at Sydney Eye Hospital, has already shown promising results, allowing the patient to see le...

TechCrunch· Oct 14, 2026 · 1:00 AM · 3 views

Video won't play? Watch on YouTube →

Science Corporation has successfully implanted its vision-restoring chip in the first patient with Stargardt disease. The tiny PRIMA implant, placed at Sydney Eye Hospital, has already shown promising results, allowing the patient to see letters and read a word during initial rehabilitation.

Full story and more reels: https://newsreel.video #news #breaking #health #technology #vision

Originally reported by TechCrunch. Read the full story →

More in Tech

Robot seized by German police after allegedly groping teenage girl

BBC News· 1 hour ago

‘Unfinished business’: the people who want their AI chatbots to ‘live on’ after they die

The Guardian· 2 hours ago

Industrial Next wants factory robots to switch tasks in minutes, not weeks

TechCrunch· 2 hours ago

0 Comments

No comments yet. Be the first.